Top Medical News
Dip in serum cholesterol tied to higher pancreatic cancer risk
Tristan Manalac, Yesterday
A recent decrease in total cholesterol levels may signal an aggravated risk of pancreatic cancer, reports a study. On the other hand, high serum cholesterol in the preceding years may exert a protective effect against pancreatic cancer.
Gut microbiome modulation reduces infections
Christina Lau, Yesterday

A gut microbiota–derived synbiotic formula developed by researchers from the Chinese University of Hong Kong (CUHK) is shown in a randomized controlled trial to reduce the risk of bacterial and viral infections, including COVID-19, reduce the risk of adverse events (AEs) after COVID-19 vaccination, restore healthy gut microbiota, and provide other health benefits.

Pharmacist-led smoking cessation program prompts quit attempts, IBD medication use
2 days ago
A smoking cessation program led by a pharmacist in a specialty medical home is feasible and may even lead to successful quit attempts and improved use of inflammatory bowel disease (IBD) medications, suggest the results of a study.
Any polyps spell risk of colorectal cancer
3 days ago
Patients with sporadic ampullary tumours more commonly have colorectal polyps or neoplasia than healthy controls, a recent study has found.
ENT-01 relieves constipation in patients with Parkinson’s disease
4 days ago
Oral ENT-01 safely and significantly improves constipation in patients with Parkinson’s disease (PD), results of a phase IIb study have shown.
Lactobacillus probiotics provide little relief for diarrhoea
Tristan Manalac, 4 days ago
A recent meta-analysis has showed little evidence supporting the use of probiotics containing a combination of Lactobacillus acidophilus and L. bulgaricus for the treatment of diarrhoea.
Esophagogastric junction biopsy may be forgone after endoscopic eradication of BE
4 days ago
Random histological sampling from the esophagogastric junction (EGJ) appears to hold low clinical relevance in patients who have undergone successful endoscopic eradication of all visible Barrett’s esophagus (BE), given that the incidence of intestinal metaplasia at the EGJ does not pose a higher risk of disease recurrence, according to a study.
Special Reports
Product Highlight - Ravida
13 Sep 2022
Ravidasvir 200 mg tab
Product Highlight - Salofalk
12 Mar 2021
SALOFALK – Mesalazine 1.5 g PR granules
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
Could a single screening colonoscopy prevent CRC?
Roshini Claire Anthony, 16 Nov 2022

Results of the NordICC* trial from Europe, presented at the United European Gastroenterology Week (UEG 2022), have hinted at the benefit of a single screening colonoscopy in preventing colorectal cancer (CRC).

Is vonoprazan an alternative to pantoprazole in preventing post-EVL ulcers, bleeding?
Roshini Claire Anthony, 08 Nov 2022

Vonoprazan may be as effective as pantoprazole in reducing the risk of ulcers or bleeding following endoscopic variceal ligation (EVL) in patients with portal hypertension, according to a small study from Egypt presented at the United European Gastroenterology Week (UEG 2022).

Tucatinib-trastuzumab combo induces durable tumour response in HER2+ mCRC
Elvira Manzano, 19 Sep 2022
Dual HER-2 inhibition with tucatinib and trastuzumab induces clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) in the phase II MOUNTAINEER trial, boosting hopes for this chemotherapy-free combination.
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
Roshini Claire Anthony, 14 Sep 2022

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
Roshini Claire Anthony, 11 Sep 2022

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

Second-line NIVO + IPI combo sustains response, OS benefit in aHCC
Elaine Soliven, 30 Aug 2022
The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.
Durvalumab + gemcitabine-cisplatin confers benefit in biliary tract cancer
Roshini Claire Anthony, 27 Aug 2022

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.